Biotech News & Trading Forum: Community User: Weedmaster

Biophytis mit guten News heute morgen ,,Marktkap unfassbare €4 M -----Good News ... https://www.biophytis.com/wp-content/uploads/2019/12/20191209-BIOPHYTIS-SCWD-Presentation-PR-EN-Final.pdf....... Dr SamuelAgus, CMO of Biophytis,said “We are pleased to have theopportunity to present the SARA-OBS preliminary analysisat SCWD. The SARA-OBS studywas designed to characterize a population of sarcopenic patients to be included in the SARA-INT Phase 2bstudy and the preliminary data shows that we are recruiting the right patient population, namely patients with severe sarcopenia that are at a high risk for mobility disability. Based on thesepreliminaryfindings we would expect the SARA-INT trial to show that Sarconeos (BIO101) delivers a larger treatment effect versus placebothan initially anticipated.These dataprovide us with greater confidence that the SARA-INT study will deliver a positive outcome andfurther emphasizesthe potential of Sarconeos (BIO101) as a treatment for neuromuscular diseases.”

LentiGlobin - HGB-210 Sickle Cell Disease (SCD) Phase 2 Phase 3 trial to be initiated by end of 2019. LentiGlobin - HGB-212 Northstar-3 TDT and the β0/β0genotype Phase 3 Phase 3 presentation of data at ASH December 9, 2019, 5:30 p.m ET. bb2121 - KarMMa Relapsed/refractory multiple myeloma Phase 2 Phase 2 data due by the end of 2019. LentiGlobin - HGB-207 Northstar-2 non-β0/β0 transfusion-dependent thalassemia (TDT) Phase 3 Phase 3 presentation of data at ASH December 9, 2019, 6pm. Lenti-D - Starbeam Childhood cerebral adrenoleukodystrophy (CCALD) Phase 2/3 Phase 2/3 updated data September 18, 2019 noted 88% (N=15/17) continue to be alive and MFD-free. LentiGlobin - HGB-204 β-Thalassemia Phase 1/2 Updated data due at EHA June 14, 2019 noted 3.8 years of transfusion independence in patients who do not have a β0/β0 genotype. LentiGlobin - HGB-206 Sickle disease Phase 1/2 Phase 1/2 presentation of data due at ASH December 7, 2019, 5:30pm. bb21217 Multiple Mye loma Phase 1 Phase 1 data due at ASH December 9, 2019, 6:45 p.m. ET.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 9, 2019 at 8:00 p.m. ET to review clinical data presented at the 61st American Society of Hematology Annual Meeting and Exposition.

Hat schonmal wer was von Diffusion Pharma (US2537483057 · A2PAYY) gehört? Da soll es morgen eine Präsentation geben, Cash bis ~ende 2020 soll vorhanden sein. Hab das vorhin auf Stock. Wits gesehn 🤔🤔

BRUTALST unterbewertete Bioperle ....Biophytis =Kurs 0,21 --Marktkap €4,2 M -- Phase 2b Studie (Sarkopenie) läuft ,Interimanalyse im1Q erwartet -- Start Phase 1/2 (DMD) in kürze , IND approval diese oder nächste Woche = Unendeckte Aktie mit MULTIBAGGER Potenzial .....mehr infos hier...https://www.wallstreet-online.de/diskussion/1316420-1-10/albps-pa-mkap-2-9-m-attraktive-pipeline-u-spottbillig

Auris Medical hat Q4 oder spätestens Q1 noch 2 Katalysatoren. Äußerst geringe Aktienzahl und MK: Market Capitalization 4,557,635$ Number of Shares 3,302,634 Phase 2 Daten zu AM-125 Phase 1 B Daten zu AM-201

Dann haben wir was gemeinsam 😂

Dann guck dir correvio an Moma,heiße Kiste aber nach dem Rutsch am Freitag auch ne Mega Chance.

Billi, ich liebe heiße Kisten. 😅

Ist eine heiße Kiste Moma 🤔 Dann hoffen wir das die Studie mit NRG besser ausfällt

Billi, ich erwarte einen Rebound.

晚上好, so China-Einsatz beendet 🍾🍾. Jetzt kann es wieder weitergehen. A wie Akari Therapeutics: http://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-reports-third-quarter-2019-financial-results Eventuell Phase 3 Daten zu Coversin - CAPSTONE gegen Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1/2 Part B Daten zu Coversin gegen Atopic keratoconjunctivitis Start Phase 3 Studie zu Coversin Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)

🖐🏻 Billi.....

Leni👋